Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- CheckyesterdayChange DetectedThe page history shows a new revision label from v3.3.3 to v3.3.4, which is a minor backend update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a footer notice 'Revision: v3.3.3'. Removed the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' reference.SummaryDifference0.1%

- Check44 days agoChange DetectedThe history now includes additions for Contacts/Locations and Study Status. A deletion on 2024-11-14 removes a prior data item from the record.SummaryDifference0.3%

- Check51 days agoChange DetectedA new revision entry v3.3.2 has been added to the history, and the previous v3.2.0 entry has been removed.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoved the site-wide operating status notice about government funding. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedVersion history indicates multiple entries updating Study Status and Contacts/Locations for NCT05013229, reflecting ongoing status and site information changes.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.